Skip to main content

Advertisement

SpringerLink
Log in

Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Cardiovascular disease is the primary cause of death among women in the United States, in part due to a very high prevalence of dyslipidemia. Clinical trials have shown that low-density lipoprotein cholesterol-lowering therapy can decrease angiographic progression of coronary disease and decrease clinical events among women and men. Although hormone replacement therapy has beneficial effects on the lipoprotein profile, its role in cardiovascular disease prevention remains unclear. The recently released Third Report of the National Cholesterol Education Program Expert Panel provides detailed guidelines for the management of dyslipidemia in women, with a focus on low-density lipoprotein cholesterol and intensity guided by risk of cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association: 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2000.

    Google Scholar 

  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 93-3095, September 1993.

  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497. New US guidelines for the assessment and treatment of hyperlipidemia.

  4. Liao Y, McGee DL, Cooper RS: Prediction of coronary heart disease mortality in blacks and whites: pooled data from two national cohorts. Am J Cardiol 1999, 84:31–36.

    Article  PubMed  CAS  Google Scholar 

  5. Manolio TA, Pearson TA, Wenger NK, et al.: Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992, 2:161–176.

    Article  PubMed  CAS  Google Scholar 

  6. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascular Risk 1996, 3:213–219.

    Article  CAS  Google Scholar 

  7. Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007–3012.

    Article  PubMed  CAS  Google Scholar 

  8. Waters D, Higginson L, Gladstone P, et al., for the CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959–968.

    PubMed  CAS  Google Scholar 

  9. Ballantyne CM, Herd JA, Schein JR, et al.: Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS). CVR&R 1998, 12–24.

  10. Campeau L, Hunninghake DB, Knatterud GL, et al., and the Post CABG Trial Investigators: Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft Clinical Trial. Circulation 1999, 99:3241–3247.

    PubMed  CAS  Google Scholar 

  11. Byington RP, Jukema JW, Salonen JT, et al.: Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995, 92:2419–2425.

    PubMed  CAS  Google Scholar 

  12. Miettinen TA, Pyoeraelae K, Olsson A, et al., for the Scandinavian Simvastatin Study Group: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997, 96:4211–4218.

    PubMed  CAS  Google Scholar 

  13. Lewis SJ, Sacks FM, Mitchell JS, et al., for the CARE Investigators: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Coll Cardiol 1998, 32:140–146.

    Article  PubMed  CAS  Google Scholar 

  14. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.

    Article  Google Scholar 

  15. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  16. LaRosaJC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346. Meta-analysis of the major statin trials that provides subgroup data by gender and age.

    Article  Google Scholar 

  17. Fonarow GC, French WJ, Parsons LS, et al., for the National Registry of Myocardial Infarction 3 Participants: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001, 103:38–44.

    PubMed  CAS  Google Scholar 

  18. Aronow HD, Topol EJ, Roe MT, et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063–1068.

    Article  PubMed  CAS  Google Scholar 

  19. Stenestrand U, Wallentin L, for the dish Register of Cardiac Intensive Care Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430–436.

    Article  PubMed  CAS  Google Scholar 

  20. Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Miocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.

    Article  PubMed  CAS  Google Scholar 

  21. Byington RP, Evans GW, Espeland MA, et al., for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group: Effects of lovastatin and warfarin on early carotid atherosclerosis. Circulation 1999, 100:e14-e17.

    PubMed  CAS  Google Scholar 

  22. Plehn JF, Davis BR, Sacks FM, et al., for the CARE Investigators: Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999, 99:216–223.

    PubMed  CAS  Google Scholar 

  23. Ross SD, Allen IE, Connelly JE, et al.: Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999, 159:1793–1802.

    Article  PubMed  CAS  Google Scholar 

  24. Bittner V, Simon JA, Fong J, et al.: Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J 2000, 139:288–296.

    PubMed  CAS  Google Scholar 

  25. Hu FB, Stampfer MJ, Manson JAE, et al.: Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000, 343:530–537.

    Article  PubMed  CAS  Google Scholar 

  26. Hu FB, Stampfer MJ, Manson JAE, et al.: Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997, 337:1491–1499.

    Article  PubMed  CAS  Google Scholar 

  27. Anderson JW, Allgood LD, Lawrence A, et al.: Cholesterollowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000, 71:472–479.

    PubMed  CAS  Google Scholar 

  28. Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995, 333:1308–1312.

    Article  PubMed  CAS  Google Scholar 

  29. Gylling H, Radhakrishnan R, Miettinen TA: Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation 1997, 96:4226–4231.

    PubMed  CAS  Google Scholar 

  30. Vuorio AF, Gylling H, Turtola H, et al.: Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000, 20:500–506.

    PubMed  CAS  Google Scholar 

  31. Blair SN, Capuzzi DM, Gottlieb SO, et al.: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000, 86:46–52.

    Article  PubMed  CAS  Google Scholar 

  32. Stefanick ML, Mackey S, Sheehan M, et al.: Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998, 339:12–20.

    Article  PubMed  CAS  Google Scholar 

  33. Warner JG, Brubaker PH, Zhu Y, et al.: Long-term (5-year) changes in HDL cholesterol in cardiac rehabilitation patients: do sex differences exist? Circulation 1995, 92:773–777.

    PubMed  Google Scholar 

  34. Anderson RE, Wadden TA, Bartlett SJ, et al.: Effects of lifestyle activity vs. structured aerobic exercise in obese women: a randomized trial. JAMA 1999, 281:335–340. Randomized trial of two physical activity interventions that shows that lifestyle activity, which may be easier to implement for women, especially older women, is associated with significant benefit.

    Article  Google Scholar 

  35. Olson MB, Kelsey SF, Bittner V, et al., for the Women’s Ischemia Syndrome Evaluation (WISE) Study Group: Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect. A report from the NHLBI-sponsored WISE Study. J Am Coll Cardiol 2000, 36:1565–1571. Provocative data on the impact of weight cycling on HDL-C in women. The study is limited by its cross-sectional design and the retrospective ascertainment of weight cycling, but points to a potentially very important side effect of repeated unsuccessful attempts to control body weight over time.

    Article  PubMed  CAS  Google Scholar 

  36. Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M: Effects of walking training on weight maintenance after a very-low-energy diet in premenopausal obese women. Arch Intern Med 2000, 160:2177–2184.

    Article  PubMed  CAS  Google Scholar 

  37. Ory SJ, Field CS, Herrmann RR, et al.: Effects of long-term transdermal administration of estradiol on serum lipids. Mayo Clin Proc 1998, 73:735–738.

    Article  PubMed  CAS  Google Scholar 

  38. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995, 273:199–208.

    Article  Google Scholar 

  39. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/ progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613.

    Article  PubMed  CAS  Google Scholar 

  40. Herrington DM, Reboussin DM, Broshnihan KB, et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522–529.

    Article  PubMed  CAS  Google Scholar 

  41. Bittner V: Estrogen, lipids and cardiovascular disease: no easy answers. J Am Coll Cardiol 2001, 37:431–433.

    Article  PubMed  CAS  Google Scholar 

  42. Shlipak MG, Simon JA, Vittinghoff E, et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart events after menopause. JAMA 2000, 283:1845–1852. Subgroup analysis of the HERS trial. Points out that Lp(a) is a significant predictor of events among postmenopausal women with coronary heart disease. Also suggests that women with high Lp(a) may benefit from hormone replacement therapy.

    Article  PubMed  CAS  Google Scholar 

  43. Davidson MH, Testolin LM, Maki KC, et al.: A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997, 157:1186–1192.

    Article  PubMed  CAS  Google Scholar 

  44. Sbarouni E, Kyriakides ZS, Kremastinos DTH: The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998, 32:1244–1250.

    Article  PubMed  CAS  Google Scholar 

  45. Herrington DM, Werbel BL, Riley WA, et al.: Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999, 33:2030–2037.

    Article  PubMed  CAS  Google Scholar 

  46. Cox JL: Lipid-lowering drugs in pregnancy and lactation. In Cardiac Problems in Pregnancy, edn 3. Edited by Elkayam U, Gleicher N. New York: Wiley-Liss; 1998:445–449.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Disease, University of Alabama at Birmingham, UAB Station - LHR 310, 35294, Birmingham, AL, USA

    Vera Bittner MD, MSPH

Authors
  1. Vera Bittner MD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bittner, V. Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease. Curr Cardiol Rep 3, 401–407 (2001). https://doi.org/10.1007/s11886-001-0057-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-001-0057-2

Keywords

Search

Navigation